Capricor Therapeutics Inc

Capricor Therapeutics maintains a pristine balance sheet characterized by zero debt and substantial liquidity. The company holds $287.8 million in cash and equivalents against total liabilities of $50.2 million, resulting in a debt-to-equity ratio of 0.0. This strong liquidity position supports a market capitalization of $1.16 billion and a price-to-book ratio of 3.81, indicating that investors are pricing in significant future value creation despite the absence of current earnings. The company’s total assets stand at $355.9 million, with total equity at $305.8 million, providing a robust buffer for ongoing operations.

Profitability metrics reflect the typical profile of a pre-revenue biotechnology firm. The company reports zero revenue and an operating income of -$108.1 million, leading to a net income loss of -$105.0 million. Consequently, return on equity is -37.47% and return on assets is -32.19%. These negative returns are driven by high operating expenses associated with research and development, which are necessary to advance its pipeline. The negative EV/EBITDA of -7.31 further underscores the current lack of profitability, a standard condition for companies in this stage of development.

As a pre-commercial entity, Capricor Therapeutics does not report segmented revenue or geographic sales data. The entire business model is concentrated on the advancement of its clinical pipeline. Revenue concentration risk is therefore not applicable in the traditional sense, as there are no commercial sales to diversify. The company’s value is derived entirely from the potential future commercialization of its therapeutic candidates, making the success of its clinical trials the sole driver of future revenue streams.

Growth trajectory analysis is limited by the absence of historical revenue data, as the company has not yet generated sales. The financial snapshot indicates a single period of operation with zero revenue. Without a history of sales growth, traditional growth metrics cannot be calculated. The company’s progression is instead measured by clinical milestones and regulatory approvals, which are not captured in the financial revenue history. The focus remains on capital preservation and efficient burn rate management to reach these non-financial milestones.

Risk assessment indicates low liquidity risk and low dilution risk. The company has no immediate filing-based liquidity or dilution flags. The substantial cash reserve of $287.8 million provides a long runway for operations, reducing the immediate need for equity financing that could dilute shareholders. The absence of debt eliminates interest rate risk and covenant compliance issues. However, the primary risk remains the binary outcome of clinical trials and the potential for future dilution if additional capital is required beyond the current cash position.

Recent observations highlight strong analyst sentiment, with a mean price target of $53.60 and a median target of $52.50, significantly above the current market price of $20.30. The mean recommendation is 1.80, with 10 analysts issuing buy or strong-buy ratings and no hold ratings. This suggests that the market perceives significant upside potential in the company’s pipeline. No recent negative news events or filing observations were detected that would alter this positive outlook.

Analysts project 164% upside to a mean price target of $53.60, signaling strong institutional confidence in future valuation.

The company maintains a low leverage band with a debt-to-equity ratio of 0.164, indicating a conservative capital structure.

A current ratio of 9.01 suggests robust short-term liquidity, minimizing immediate solvency concerns despite operating losses.

Liquidity and dilution risks are assessed as low, providing a stable financial foundation for ongoing operations.

Revenue reached $25.2 million in FY2024, demonstrating the company's ability to generate some operating income before recent declines.

Cash conversion ratio of 0.61 is below the cohort median of 0.72, suggesting weaker ability to convert earnings into cash.

Revenue $0.00; Operating income −47,2% YoY.

• ▍Revenue $0.00
• ▍Operating income −47,2% YoY
• ▍Net income −39,1% YoY
• ▍Free cash flow −75,7% YoY

Revenue $0.00, −100,0% YoY; Operating income −278,8% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −278,8% YoY
• ▍Net income −323,9% YoY
• ▍Free cash flow −365,4% YoY

Revenue $0.00, −100,0% YoY; Operating income −102,0% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −102,0% YoY
• ▍Net income −95,7% YoY
• ▍Free cash flow −129,2% YoY

Revenue $0.00, −100,0% YoY; Operating income −139,1% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −139,1% YoY
• ▍Net income −135,6% YoY
• ▍Free cash flow −150,6% YoY

Revenue $0.00; Operating income -$25.0M.

• ▍Revenue $0.00
• ▍Operating income -$25.0M

Revenue $11.1M; Operating income -$7.7M.

• ▍Revenue $11.1M
• ▍Operating income -$7.7M
• ▍Net margin -63.9%

Revenue $2.3M; Operating income -$13.0M.

• ▍Revenue $2.3M
• ▍Operating income -$13.0M
• ▍Net margin -555.2%

Revenue $4.0M; Operating income -$11.6M.

• ▍Revenue $4.0M
• ▍Operating income -$11.6M
• ▍Net margin -277.0%

Revenue $0.00, −100,0% YoY; Operating income −154,1% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −154,1% YoY
• ▍Net income −159,6% YoY
• ▍Free cash flow −183,1% YoY

Revenue $22.3M, −11,6% YoY; Operating income −76,8% YoY.

• ▍Revenue $22.3M, −11,6% YoY
• ▍Operating income −76,8% YoY
• ▍Net income −81,6% YoY
• ▍Free cash flow −74,4% YoY
• ▍Net margin -181.7%

Revenue $25.2M, +886,8% YoY; Operating income +18,9% YoY.

• ▍Revenue $25.2M, +886,8% YoY
• ▍Operating income +18,9% YoY
• ▍Net income +23,2% YoY
• ▍Free cash flow +26,9% YoY
• ▍Net margin -88.5%

Revenue $2.6M, +941,8% YoY; Operating income −44,0% YoY.

• ▍Revenue $2.6M, +941,8% YoY
• ▍Operating income −44,0% YoY
• ▍Net income −44,9% YoY
• ▍Free cash flow −51,8% YoY
• ▍Net margin -1137.4%